Please use this identifier to cite or link to this item:
http://elar.urfu.ru/handle/10995/101482
Title: | HIV/SARS-CoV-2 coinfection: A global perspective |
Authors: | Kanwugu, O. N. Adadi, P. |
Issue Date: | 2021 |
Publisher: | John Wiley and Sons Inc |
Citation: | Kanwugu O. N. HIV/SARS-CoV-2 coinfection: A global perspective / O. N. Kanwugu, P. Adadi. — DOI 10.1002/jmv.26321 // Journal of Medical Virology. — 2021. — Vol. 93. — Iss. 2. — P. 726-732. |
Abstract: | Since its first appearance in Wuhan, China, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread throughout the world and has become a global pandemic. Several medical comorbidities have been identified as risk factors for coronavirus disease 2019 (COVID-19). However, it remains unclear whether people living with human immunodefeciency virus (PLWH) are at an increased risk of COVID-19 and severe disease manifestation, with controversial suggestion that HIV-infected individuals could be protected from severe COVID-19 by means of antiretroviral therapy or HIV-related immunosuppression. Several cases of coinfection with HIV and SARS-CoV-2 have been reported from different parts of the globe. This review seeks to provide a holistic overview of SARS-CoV-2 infection in PLWH. © 2020 Wiley Periodicals LLC |
Keywords: | ANTIRETROVIRAL THERAPY/COINFECTION COVID-19 HIV IMMUNODEFICIENCY CLINICAL FEATURE COMORBIDITY CORONAVIRUS DISEASE 2019 DISEASE ASSOCIATION DISEASE SEVERITY HIGH INCOME COUNTRY HUMAN HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION INFECTION RISK MIXED INFECTION NONHUMAN PANDEMIC REVIEW VIRUS LOAD ADULT CD4+ T LYMPHOCYTE DIABETES MELLITUS DRUG EFFECT FEMALE GROWTH, DEVELOPMENT AND AGING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY HUMAN IMMUNODEFICIENCY VIRUS HUMAN IMMUNODEFICIENCY VIRUS INFECTION HYPERTENSION IMMUNOCOMPROMISED PATIENT IMMUNOLOGY MALE MIDDLE AGED MIXED INFECTION MORTALITY PANDEMIC PATHOGENICITY PATHOPHYSIOLOGY SURVIVAL ANALYSIS TREATMENT OUTCOME VIROLOGY ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT ADULT ANTI-HIV AGENTS ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE CD4-POSITIVE T-LYMPHOCYTES COINFECTION COMORBIDITY COVID-19 DIABETES MELLITUS FEMALE HIV HIV INFECTIONS HUMANS HYPERTENSION IMMUNOCOMPROMISED HOST MALE MIDDLE AGED PANDEMICS SARS-COV-2 SURVIVAL ANALYSIS TREATMENT OUTCOME |
URI: | http://elar.urfu.ru/handle/10995/101482 |
Access: | info:eu-repo/semantics/openAccess |
RSCI ID: | 45488979 |
SCOPUS ID: | 85088583592 |
WOS ID: | 000552989400001 |
PURE ID: | 20377699 51bf165d-0ab5-4bcc-a955-a0fad89dc5b3 |
ISSN: | 1466615 |
DOI: | 10.1002/jmv.26321 |
Appears in Collections: | Научные публикации ученых УрФУ, проиндексированные в SCOPUS и WoS CC |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
2-s2.0-85088583592.pdf | 1,12 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.